FDA QIDP Designation for Motif’s Lead Antibiotic Candidate Iclaprim For ABSSSI

Published: Jul 23, 2015

Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that the U.S. Food & Drug Administration (FDA) has designated iclaprim, a broad-spectrum antibiotic designed to be effective against multi-drug resistant bacteria, as a Qualified Infectious Diseases Product (QIDP) for acute bacterial skin and skin structure infections (ABSSSI).

The Company requested QIDP designation for iclaprim for two serious and life threatening infections, hospital acquired bacterial pneumonia (HABP) and ABSSSI. QIDP designation has already been confirmed for HABP.

QIDP designation, provided under the Generating Antibiotic Incentives Now Act (GAIN Act), makes iclaprim eligible for certain incentives, including priority review and fast track designation. With QIDP designation, iclaprim is now eligible for an additional five-year extension of Hatch-Waxman exclusivity, for a total of 10 years of market exclusivity, starting from the date of NDA approval.

Graham Lumsden, CEO of Motif Bio plc, said:

"QIDP designation for iclaprim has now been confirmed for the two serious and life threatening infections that we applied for. This is an important value driver for iclaprim and another positive development for Motif and our investors. We believe that iclaprim is the first and only dihydrofolate reductase inhibitor to receive the QIDP designation."

Enquiries

Motif Bio plc

Graham Lumsden (Chief Executive Officer)
Robert Bertoldi (Chief Financial Officer)
www.motifbio.com

Zeus Capital Limited (Nominated Advisor and Broker)

+44 (0) 207 533 7727
Phil Walker / John Treacy
Dominic Wilson

Northland Capital Partners Limited (Broker)

+44 (0) 20 7382 1100
Patrick Claridge/David Hignell
John Howes/Mark Treharne (Broking)

Plumtree Capital Limited (Financial Advisor)

Stephen Austin
+44 (0) 207 183 2493

MC Services AG (Public Relations)

Raimund Gabriel
+49 (0) 89 210 2280
Shaun Brown
+44 (0) 207 148 5998

Yellow Jersey PR Limited (Investor Relations)

Dominic Barretto
Fiona Walker
+44 (0) 7768 537 739

Help employers find you! Check out all the jobs and post your resume.

Back to news